You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Authors’ response to Metzdorf et al
  1. Christine R Jenkins1,
  2. Richard Beasley2
  1. 1 The George Institute for Global Health, Sydney, Australia
  2. 2 Medical Research Institute of New Zealand, Wellington, New Zealand
  1. Correspondence to Dr Christine R Jenkins, The George Institute for Global Health, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia; christine.jenkins{at}sydney.edu.au

https://doi.org/10.1136/thoraxjnl-2013-203380

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the contribution to this discussion from Metzdorf et al 1, and the efforts made by the company to assess the safety of the Handihaler and Respimat through pooling datasets from randomised controlled trials. We would like reassurance that the pooled analysis of the three 1-year and one 6-month placebo-controlled trials with Spiriva Respimat detailed on the product information website was based on an intention to treat …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles